Sun Pharma gets US FDA nod for its specialty drug against baldness

Sun Pharma announced FDA approval of Leqselvi (deuruxolitinib) 8 mg tablets for severe alopecia areata, marking a major milestone after acquiring Concert Pharmaceuticals for $576 million. The drug, with a five-year marketing exclusivity, boosts Sun Pharma's specialty business. Shares rose 2.58%. Clinical trials showed significant hair regrowth in patients